SOD Activity Testing for Early Mild Cognitive Impairment Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods are inadequate for early detection and intervention in mild cognitive impairment (MCI), necessitating a reliable test method and reagent to identify and potentially slow down the progression of cognitive impairment.

Innovation Solution

A test method and reagent that measure superoxide dismutase (SOD) activity in biological samples, using Electron Spin Resonance (ESR) to detect MCI and screen for therapeutic candidates that enhance SOD activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional diagnostic methods (doctor's interview) are used for MCI detection, then the diagnosis can be performed with simple procedures, but the detection capability for early-stage MCI is insufficient

Engineering Contradiction:

ImproveMCI detection capabilityVSAvoidtest method complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent replaces the mechanical/manual diagnostic process (doctor's interview and assessment) with a biochemical measurement system that detects SOD activity levels in biological samples. This substitution enables objective, quantitative detection of MCI through enzymatic activity measurement, significantly improving detection precision while maintaining operational simplicity through standardized assay procedures

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces SOD activity measurement as an intermediary biomarker that connects the underlying pathological changes in MCI to detectable clinical signs. By measuring SOD activity in saliva or blood samples, the system provides an indirect but reliable indicator of cognitive impairment status, enabling early detection before significant cognitive symptoms manifest

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If early intervention in MCI stage is implemented to slow progression, then therapeutic effectiveness is improved, but the ability to detect MCI early is currently insufficient

Engineering Contradiction:

Improveearly detection reliabilityVSAvoiddetection time delay

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent enables preliminary detection of MCI by measuring SOD activity before significant cognitive impairment occurs. By identifying elevated SOD activity as an early biomarker, the system allows intervention to be initiated in the pre-symptomatic or early symptomatic stage, maximizing therapeutic effectiveness and preventing progression to severe dementia

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent replaces time-consuming comprehensive cognitive assessments with a rapid SOD activity measurement that can be performed quickly on biological samples. This substitution dramatically reduces the time required for detection while maintaining high reliability, enabling timely intervention decisions

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables early detection of MCI through SOD activity measurement, facilitating targeted interventions and therapeutic candidate identification.

Implementation Method 1

using Electron Spin Resonance (ESR) to detect MCI

Methodology Applied

Scientific EffectElectron Spin Resonance: Electron Paramagnetic Resonance

Data Source

PatentUS20260062733A1Test method for mild cognitive impairment, test reagent for mild cognitive impairment, and method for screening therapeutic candidate substances for mild cognitive impairment

Publication Date: 2026.03.05 BIORADICAL RES INST CORP

AI summary

Provided is a test method with which mild cognitive impairment (MCI) is detectable and a measurement reagent for use in the test method. A test method for MCI according to the present invention includes a step of measuring the activity of superoxide dismutase (SOD) in a biological sample of a subject.